 |
0 Diseases |  |
7 Trials |
|
7 Trials |  |
135 News |  |
| «12 |
- Zygel (cannabidiol gel) / Zynerba
Cannabidiol Transdermal Gel for the Treatment of Fragile X Syndrome: Post hoc Responder Analysis and Pattern of Efficacy on domains of the Aberrant Behavior Checklist-FXS (ABC-CFXS) () - Jan 21, 2020 - Abstract #AAN2020AAN_1828;
The majority of FXS patients treated with open-label ZYN002 met an important criterion for response on the ABC-CFXS. Simultaneous visualization of change across all measured domains of the ABC-CFXS (“radar charts”) provided evidence of more global, multi-domain reduction in behavioral symptom burden, and may provide evidence to support the efficacy of ZYN002 CBD transdermal gel in FXS.
- |||| Zygel (cannabidiol gel) / Paragon Biosci
Trial completion date, Trial primary completion date: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) (clinicaltrials.gov) - Jan 18, 2020
P2/3, N=204, Recruiting, Sponsor: Zynerba Pharmaceuticals, Inc.
Simultaneous visualization of change across all measured domains of the ABC-CFXS (“radar charts”) provided evidence of more global, multi-domain reduction in behavioral symptom burden, and may provide evidence to support the efficacy of ZYN002 CBD transdermal gel in FXS. Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Jul 2019 --> May 2020
- |||| Zygel (cannabidiol gel) / Paragon Biosci
Trial completion date, Trial primary completion date: ZYN2-CL-017: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents with FXS (clinicaltrials.gov) - Jan 18, 2020
P2/3, N=300, Recruiting, Sponsor: Zynerba Pharmaceuticals, Inc.
Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Jul 2019 --> May 2020 Trial completion date: Sep 2020 --> Feb 2022 | Trial primary completion date: Sep 2019 --> Feb 2022
- ||| Zygel (cannabidiol gel) / Zynerba
CBD gel, ZYN002, improves emotional and behavioral symptoms in fragile X syndrome. https://t.co/KK1yH5XPxu #APAAM19 (Twitter) - May 21, 2019
- |||||||||| Zygel (cannabidiol gel) / Paragon Biosci
New P2/3 trial: ZYN2-CL-017: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents with FXS (clinicaltrials.gov) - Jan 14, 2019
P2/3, N=300, Recruiting, Sponsor: Zynerba Pharmaceuticals, Inc.
- | Zygel (cannabidiol gel) / Paragon Biosci
Enrollment open: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) (clinicaltrials.gov) - Oct 9, 2018
P2/3, N=204, Recruiting, Sponsor: Zynerba Pharmaceuticals, Inc.
Trial completion date: Sep 2020 --> Feb 2022 | Trial primary completion date: Sep 2019 --> Feb 2022 Not yet recruiting --> Recruiting
- | Zygel (cannabidiol gel) / Paragon Biosci
New P2/3 trial: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) (clinicaltrials.gov) - Aug 3, 2018
P2/3, N=204, Not yet recruiting, Sponsor: Zynerba Pharmaceuticals, Inc.